Want to see HK:2159 full AI Analyst Report?
Mediwelcome Healthcare Management & Technology Inc. (2159) AI Stock Analysis
Top Page
Mediwelcome Healthcare Management & Technology Inc.
(HKEX:2159)
Overall score is held back primarily by uneven financial quality: despite strong 2025 revenue growth and a return to net profitability, operating margins are very thin and cash-flow consistency remains weak. Technicals are supportive with price above key moving averages and a positive MACD, but overbought signals (RSI ~70) add near-term risk. Valuation is a notable headwind given the high P/E and no dividend yield provided.
Mediwelcome Healthcare Management & Technology Inc. (2159) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 514.84M
- Dividend Yield
- ―
- Average Volume (3M)
- 114.64K
- Price to Earnings (P/E)
- 9.6
- Beta (1Y)
- 0.81
- Revenue Growth
- 91.32%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 150
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Mediwelcome Healthcare Management & Technology Inc. Business Overview & Revenue Model
Company Description
As an investment holding entity, Mediwelcome Healthcare Management & Technology Inc. delivers comprehensive marketing solutions for the healthcare sector within the People's Republic of China. Its service portfolio encompasses medical conference orga...
Mediwelcome Healthcare Management & Technology Inc. Financial Statement Overview
Summary
Financials show a 2025 turnaround with 48.05% revenue growth and a return to net profitability (2.13% net margin). However, operating profitability remains near break-even (0.39% operating margin) and cash-flow stability is still weak after multiple cash-burning years; 2025 operating cash flow is small versus revenue (coverage ratio 0.03) and free cash flow fell 76.03% year over year.
Income Statement
54NeutralBalance Sheet
63PositiveCash Flow
42Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 568.69M | 468.02M | 321.56M | 331.31M | 323.37M | 708.36M |
| Gross Profit | 141.70M | 94.71M | 51.00M | 29.89M | 32.55M | 93.60M |
| EBITDA | 30.45M | 6.67M | -25.86M | -74.53M | -69.08M | 26.17M |
| Net Income | 33.77M | 9.99M | -45.24M | -94.10M | -89.20M | 4.64M |
Balance Sheet | ||||||
| Total Assets | 447.83M | 190.57M | 194.09M | 214.32M | 317.83M | 366.70M |
| Cash, Cash Equivalents and Short-Term Investments | 138.52M | 99.36M | 71.66M | 80.35M | 154.02M | 174.83M |
| Total Debt | 65.10M | 54.49M | 47.73M | 31.13M | 26.48M | 25.18M |
| Total Liabilities | 267.64M | 85.14M | 120.81M | 94.35M | 116.97M | 73.21M |
| Stockholders Equity | 129.85M | 111.30M | 71.14M | 116.13M | 195.02M | 283.11M |
Cash Flow | ||||||
| Free Cash Flow | 3.73M | 2.47M | -27.10M | -77.18M | -22.75M | -24.73M |
| Operating Cash Flow | 4.03M | 2.88M | -14.05M | -75.58M | -18.46M | 262.00K |
| Investing Cash Flow | -6.36M | -13.28M | -326.00K | 16.46M | -8.36M | -16.77M |
| Financing Cash Flow | 46.43M | 37.34M | 5.68M | 906.00K | 54.00K | 92.84M |
Mediwelcome Healthcare Management & Technology Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2159, the sentiment is Negative. The current price of 1.57 is below the 20-day moving average (MA) of 1.63, below the 50-day MA of 1.68, and below the 200-day MA of 1.60, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 40.09 is Neutral, neither overbought nor oversold. The STOCH value of 33.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2159.
Mediwelcome Healthcare Management & Technology Inc. Peers Comparison
Overall Rating
HK:183068Neutral
HK:215860Neutral- HK:215954Neutral
HK:990651Neutral
HK:213841Neutral
HK:388641Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1830 | 68Neutral | HKD 1.43B | 8.01 | 43.78% | 12.76% | -14.68% | -13.60% |
| HK:2158 | 60Neutral | HKD 3.05B | 36.94 | 1.88% | 1.40% | 16.87% | ― |
| HK:2159 | 54Neutral | HKD 528.27M | 9.63 | 28.00% | ― | 91.32% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9906 | 51Neutral | HKD 936.00M | 23.35 | 5.59% | ― | ― | ― |
| HK:2138 | 41Neutral | HKD 645.94M | -1.61 | -25.36% | ― | -8.94% | -140.82% |
| HK:3886 | 41Neutral | HKD 1.10B | 78.09 | 0.48% | 1.10% | -3.26% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2159 | Mediwelcome Healthcare Management & Technology Inc. | 1.57 | 0.40 | 34.19% | |
| HK:9906 | Honliv Healthcare Management Group Co Ltd | 1.56 | -0.05 | -3.11% | |
| HK:1830 | Perfect Medical Health Management Limited | 1.14 | -0.08 | -6.79% | |
| HK:2138 | EC Healthcare | 0.55 | -0.10 | -16.15% | |
| HK:2158 | Yidu Tech, Inc. | 2.86 | -2.95 | -50.77% | |
| HK:3886 | Town Health International Medical Group Ltd. | 0.16 | -0.11 | -40.07% |
Mediwelcome Healthcare Management & Technology Inc. Corporate Events
Mediwelcome Completes HK$84.72 Million Share Placing to Fund Acquisition
Mediwelcome Healthcare Management & Technology Inc. has completed a placing of 56,480,000 new shares to at least six professional and institutional investors at HK$1.50 per share, raising gross proceeds of HK$84.72 million. The net proceeds of ap...
Mediwelcome Turns Profitable as AI Healthcare Platforms Power Revenue Surge
Mediwelcome Healthcare Management & Technology Inc. reported a sharp improvement in interim performance for the six months ended 30 June 2026, driven by rapid expansion of its AI digital intelligence platforms. Revenue surged 81.7% year on year t...
Mediwelcome Extends Share Placing Deadlines Amid Compliance Checks
Mediwelcome Healthcare Management & Technology Inc. has extended both the placing period and the long stop date for its planned issuance of new shares under a specific mandate. The company and its placing agent agreed to move these deadlines to 3...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026